US5776093A
(en)
*
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
MC2324A1
(fr)
*
|
1990-11-23 |
1994-01-18 |
Gen Hospital Corp |
Inhibition des interactions entre les proteines d'adherence cellulaire et les hydrates de carbone
|
US5401489A
(en)
*
|
1991-05-01 |
1995-03-28 |
University Of New Mexico |
Biomodulators as universal imaging agents
|
US5364612A
(en)
*
|
1991-05-06 |
1994-11-15 |
Immunomedics, Inc. |
Detection of cardiovascular lesions
|
US5919455A
(en)
*
|
1993-10-27 |
1999-07-06 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
US5888773A
(en)
*
|
1994-08-17 |
1999-03-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of producing single-chain Fv molecules
|
US5846782A
(en)
*
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
US6465253B1
(en)
|
1994-09-08 |
2002-10-15 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
US5559099A
(en)
*
|
1994-09-08 |
1996-09-24 |
Genvec, Inc. |
Penton base protein and methods of using same
|
US5545553A
(en)
*
|
1994-09-26 |
1996-08-13 |
The Rockefeller University |
Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
|
US5874540A
(en)
|
1994-10-05 |
1999-02-23 |
Immunomedics, Inc. |
CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
|
SE503711C2
(sv)
*
|
1994-12-14 |
1996-08-12 |
Medicarb Ab |
Flerstegsförfarande för beläggning av en intraokulär lins
|
US6127525A
(en)
*
|
1995-02-21 |
2000-10-03 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral coat protein and methods of using same
|
US5770442A
(en)
|
1995-02-21 |
1998-06-23 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral fiber protein and methods of using same
|
US6416714B1
(en)
*
|
1995-04-25 |
2002-07-09 |
Discovery Partners International, Inc. |
Remotely programmable matrices with memories
|
US6331273B1
(en)
|
1995-04-25 |
2001-12-18 |
Discovery Partners International |
Remotely programmable matrices with memories
|
US6017496A
(en)
|
1995-06-07 |
2000-01-25 |
Irori |
Matrices with memories and uses thereof
|
US5751629A
(en)
|
1995-04-25 |
1998-05-12 |
Irori |
Remotely programmable matrices with memories
|
US5874214A
(en)
|
1995-04-25 |
1999-02-23 |
Irori |
Remotely programmable matrices with memories
|
US6329139B1
(en)
|
1995-04-25 |
2001-12-11 |
Discovery Partners International |
Automated sorting system for matrices with memory
|
DE69638058D1
(de)
|
1995-06-15 |
2009-11-26 |
Crucell Holland Bv |
Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
EP0861440A1
(de)
*
|
1995-09-22 |
1998-09-02 |
Immunomedics, Inc. |
Rekombinante proteine mit mehreren disulfidbindungen und thiolsubstituierte konjugate davon
|
EP0881910A4
(de)
|
1995-12-22 |
2006-05-03 |
Immunomedics Inc |
Verwendung von immunokonjugaten zur erhöhung der effektivität von mehrstufigen kaskaden-impfstoffen
|
US6441025B2
(en)
*
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
JP3904238B2
(ja)
*
|
1996-03-20 |
2007-04-11 |
イムノメディクス, インコーポレイテッド |
グリコシル化されたヒト化b細胞特異的抗体
|
WO1997034636A1
(en)
*
|
1996-03-20 |
1997-09-25 |
Immunomedics, Inc. |
Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
|
US5891506A
(en)
*
|
1996-08-09 |
1999-04-06 |
Medtronic, Inc. |
Oxidative method for attachment of glycoproteins or glycopeptides to surfaces of medical devices
|
CA2257357C
(en)
*
|
1996-06-07 |
2010-04-13 |
Neorx Corporation |
Humanized antibodies with modified glycosylation
|
US5861308A
(en)
*
|
1996-08-21 |
1999-01-19 |
Ludwig Institute For Cancer Research |
Isolated nucleic acids associated with T cell activation and uses thereof
|
US6136274A
(en)
*
|
1996-10-07 |
2000-10-24 |
Irori |
Matrices with memories in automated drug discovery and units therefor
|
JP2001505194A
(ja)
*
|
1996-11-05 |
2001-04-17 |
ブリストル―マイヤーズ・スクイブ・カンパニー |
分枝ペプチド・リンカー
|
US6759509B1
(en)
|
1996-11-05 |
2004-07-06 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
US5816259A
(en)
*
|
1997-01-13 |
1998-10-06 |
Rose; Samuel |
Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells
|
AU6054398A
(en)
*
|
1997-02-11 |
1998-08-26 |
Immunomedics Inc. |
Stimulation of an immune response with antibodies labeled with the alpha-galactosyl epitope
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
IL131406A0
(en)
|
1997-02-21 |
2001-01-28 |
Genentech Inc |
Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
|
US6183744B1
(en)
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6306393B1
(en)
*
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6004529A
(en)
*
|
1997-04-11 |
1999-12-21 |
Nycomed Imaging As |
Chelating agents
|
US20040009166A1
(en)
*
|
1997-04-30 |
2004-01-15 |
Filpula David R. |
Single chain antigen-binding polypeptides for polymer conjugation
|
CA2288994C
(en)
|
1997-04-30 |
2011-07-05 |
Enzon, Inc. |
Polyalkylene oxide-modified single chain polypeptides
|
WO1999004637A1
(en)
|
1997-07-25 |
1999-02-04 |
The Trustees Of Boston University |
Methods and compositions for designing vaccines
|
US6673538B1
(en)
|
1997-07-25 |
2004-01-06 |
The Trustees Of Boston University |
Methods and compositions for designing vaccines
|
US6953675B2
(en)
*
|
1997-11-06 |
2005-10-11 |
Immunomedics, Inc. |
Landscaped antibodies and antibody fragments for clinical use
|
US7005504B2
(en)
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
US6458355B1
(en)
|
1998-01-22 |
2002-10-01 |
Genentech, Inc. |
Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
|
US6468532B1
(en)
|
1998-01-22 |
2002-10-22 |
Genentech, Inc. |
Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
|
WO1999055365A1
(en)
|
1998-04-30 |
1999-11-04 |
Cornell Research Foundation, Inc. |
Adenoviral vectors with tandem fiber proteins
|
US6962702B2
(en)
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
JP2002519050A
(ja)
*
|
1998-07-02 |
2002-07-02 |
ジェネンコア インターナショナル インコーポレーテッド |
炭水化物成分を有する化学的に修飾されたタンパク質
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
US20040043489A1
(en)
*
|
1998-07-08 |
2004-03-04 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
|
EP1100473A2
(de)
|
1998-07-28 |
2001-05-23 |
InnerDyne, Inc. |
Resorbierbare verabreichungsgeräte für brachytherapie und chemotherapie und entsprechende verfahren
|
WO2000015823A1
(en)
|
1998-09-11 |
2000-03-23 |
Genvec, Inc. |
Alternatively targeted adenovirus
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
US6929946B1
(en)
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
US20030099629A1
(en)
*
|
1999-03-11 |
2003-05-29 |
Immunomedics, Inc. |
Recombinant onconase and chemical conjugates and fusion proteins of recombinant onconase
|
US8383081B2
(en)
*
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
US7829064B2
(en)
*
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US8119101B2
(en)
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
US6913922B1
(en)
*
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US6492169B1
(en)
*
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US7297478B1
(en)
|
2000-09-22 |
2007-11-20 |
Large Scale Biology Corporation |
Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
|
US7067111B1
(en)
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
US7018810B1
(en)
*
|
1999-12-07 |
2006-03-28 |
Amgen Inc. |
Chordin-like molecules and uses thereof
|
US20030023043A1
(en)
*
|
2000-03-02 |
2003-01-30 |
Kazuhisa Uchida |
Method of separating and purifying protein
|
EP2295407B1
(de)
*
|
2000-03-22 |
2014-11-05 |
Solulink, Inc. |
Hydrazin- und Carbonyl-basierte bifunktionelle Vernetzungsmittel
|
EP1157999A1
(de)
*
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
|
JP2003534806A
(ja)
*
|
2000-05-31 |
2003-11-25 |
ジェンベク、インコーポレイティッド |
アデノウイルスベクターのターゲティングの方法および組成物
|
KR100784120B1
(ko)
|
2000-06-02 |
2007-12-12 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
에틸렌디시스테인(ec)-약물 접합체
|
CA2411102A1
(en)
*
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceutical Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
CA2422076A1
(en)
*
|
2000-09-18 |
2002-03-21 |
Idec Pharmaceutical Corporation |
Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
|
NZ524743A
(en)
*
|
2000-09-20 |
2004-07-30 |
Crucell Holland B |
Gene delivery vectors provided with a tissue tropism for dendritic cells provided by a viral capsid protein
|
US7235233B2
(en)
*
|
2000-09-26 |
2007-06-26 |
Crucell Holland B.V. |
Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
|
WO2002057745A2
(en)
*
|
2001-01-08 |
2002-07-25 |
Tropix, Inc. |
Dendritic chemiluminescent substrates
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
EP2301971A1
(de)
|
2001-02-20 |
2011-03-30 |
ZymoGenetics, L.L.C. |
Antikörper, die sowohl BCMA als auch TACI binden
|
ATE483161T1
(de)
*
|
2001-04-03 |
2010-10-15 |
Thermo Finnigan Llc |
Zur vereinfachung komplexer peptidgemische geeignete verfahren und kits
|
WO2002087497A2
(en)
*
|
2001-04-26 |
2002-11-07 |
Board Of Regents, The University Of Texas System |
Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
|
EP1610751A4
(de)
*
|
2001-04-26 |
2006-05-24 |
Univ Texas |
Therapeutisches mittel/ligand-konjugat-zusammensetzungen, ihre syntheseverfahren und ihre anwendung
|
EP2335728A1
(de)
|
2001-05-11 |
2011-06-22 |
Ludwig Institute for Cancer Research Ltd. |
Spezifische Bindeproteine und deren Verwendungen
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
GB0112844D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Psimei Pharmaceuticals Plc |
Neutron capture therapy
|
US7179617B2
(en)
*
|
2001-10-10 |
2007-02-20 |
Neose Technologies, Inc. |
Factor IX: remolding and glycoconjugation of Factor IX
|
US8008252B2
(en)
*
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7696163B2
(en)
*
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7795210B2
(en)
*
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US20050069962A1
(en)
*
|
2001-10-12 |
2005-03-31 |
Archer Robert M |
Antibody complexes and methods for immunolabeling
|
US8323903B2
(en)
*
|
2001-10-12 |
2012-12-04 |
Life Technologies Corporation |
Antibody complexes and methods for immunolabeling
|
US7261875B2
(en)
*
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
US20030135195A1
(en)
*
|
2002-01-16 |
2003-07-17 |
Oscar Jimenez |
Highly lubricious hydrophilic coating utilizing dendrimers
|
AU2003208415B2
(en)
|
2002-02-14 |
2009-05-28 |
Immunomedics, Inc. |
Anti-CD20 antibodies and fusion proteins thereof and methods of use
|
US8287864B2
(en)
*
|
2002-02-14 |
2012-10-16 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
DE60325184D1
(de)
|
2002-03-01 |
2009-01-22 |
Immunomedics Inc |
Rs7 antikörper
|
DK1483294T3
(da)
|
2002-03-01 |
2010-11-08 |
Immunomedics Inc |
Internaliserende anti-CD74-antistoffer og fremgangsmåder til deres anvendelse
|
US20030180292A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
US20050107310A1
(en)
*
|
2002-03-19 |
2005-05-19 |
Holick Michael F. |
Carboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
|
CA2482368A1
(en)
|
2002-04-19 |
2003-10-30 |
Zymogenetics, Inc. |
Cytokine receptor
|
IL164803A0
(en)
*
|
2002-04-25 |
2005-12-18 |
Crucell Holland Bv |
Means and methods for the production of adenovirusvectors
|
EP2301968A3
(de)
|
2002-06-14 |
2011-06-29 |
Immunomedics, Inc. |
Humanisierter monoklonaler Antikörper HPAM4
|
MXPA04012496A
(es)
|
2002-06-21 |
2005-09-12 |
Novo Nordisk Healthcare Ag |
Glicoformos del factor vii pegilados.
|
CA2489712C
(en)
*
|
2002-06-21 |
2016-07-12 |
University Of Utah Research Foundation |
Crosslinked compounds and methods of making and using thereof
|
KR101115797B1
(ko)
*
|
2002-08-01 |
2012-07-27 |
이뮤노메딕스, 인코오포레이티드 |
알파 태아 단백질 Immu31 항체 및 융합단백질, 및이들의 이용 방법
|
US7541440B2
(en)
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
US20060024289A1
(en)
*
|
2002-10-02 |
2006-02-02 |
Ruggles Sandra W |
Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
|
US7939304B2
(en)
*
|
2002-10-02 |
2011-05-10 |
Catalyst Biosciences, Inc. |
Mutant MT-SP1 proteases with altered substrate specificity or activity
|
JP4790413B2
(ja)
|
2002-10-08 |
2011-10-12 |
イミューノメディクス、インコーポレイテッド |
抗体療法
|
EP2316493A3
(de)
*
|
2002-11-07 |
2011-08-10 |
Board of Regents, The University of Texas System |
Ethylendicystein(ec)-Aarzneimittelkonjugate, Zusammensetzungen und Verfahren für die gewebsspezifische Darstellung von Krankheiten
|
EP1572106B1
(de)
|
2002-11-15 |
2010-05-05 |
Novartis Vaccines and Diagnostics, Inc. |
Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
NZ542094A
(en)
*
|
2003-03-14 |
2008-12-24 |
Neose Technologies Inc |
Branched polymer conjugates comprising a peptide and water-soluble polymer chains
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
WO2006127896A2
(en)
*
|
2005-05-25 |
2006-11-30 |
Neose Technologies, Inc. |
Glycopegylated factor ix
|
SG155777A1
(en)
*
|
2003-04-09 |
2009-10-29 |
Neose Technologies Inc |
Glycopegylation methods and proteins/peptides produced by the methods
|
EP1624847B1
(de)
|
2003-05-09 |
2012-01-04 |
BioGeneriX AG |
Zusammensetzungen und Verfahren zur Herstellung von Glykosylierungsmutanten des menschlichen Wachstumshormons
|
EP2221317A3
(de)
*
|
2003-06-30 |
2011-07-27 |
Domantis Limited |
Pegylierte Single-domain-Antikörper (dAb)
|
WO2005012484A2
(en)
*
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
US8038983B2
(en)
*
|
2003-07-29 |
2011-10-18 |
Immunomedics, Inc. |
Fluorinated carbohydrate conjugates
|
WO2005012493A2
(en)
|
2003-07-31 |
2005-02-10 |
Immunomedics, Inc. |
Anti-cd19 antibodies
|
US7083936B2
(en)
*
|
2003-08-01 |
2006-08-01 |
Beckman Coulter, Inc. |
Aminodextran compositions and conjugates and method of making and using them
|
US7842661B2
(en)
*
|
2003-11-24 |
2010-11-30 |
Novo Nordisk A/S |
Glycopegylated erythropoietin formulations
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US20080305992A1
(en)
*
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US20060040856A1
(en)
*
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
US7956032B2
(en)
*
|
2003-12-03 |
2011-06-07 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
US20080318850A1
(en)
*
|
2003-12-03 |
2008-12-25 |
Neose Technologies, Inc. |
Glycopegylated Factor Ix
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
PT2311873T
(pt)
|
2004-01-07 |
2018-11-20 |
Novartis Vaccines & Diagnostics Inc |
Anticorpo monoclonal específico para m-csf e respetivos usos
|
EP1765853B1
(de)
|
2004-01-08 |
2015-10-28 |
ratiopharm GmbH |
O-Glykosylierung von G-CSF Peptiden
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
CN104774931B
(zh)
|
2004-03-31 |
2017-11-10 |
综合医院公司 |
测定癌症对表皮生长因子受体靶向性治疗反应性的方法
|
SE0400886D0
(sv)
*
|
2004-04-02 |
2004-04-02 |
Amersham Biosciences Ab |
Process of purification
|
ATE534734T1
(de)
*
|
2004-04-12 |
2011-12-15 |
Catalyst Biosciences Inc |
Spaltung von vegf und vegf-rezeptoren durch wildtyp- und mutante mt-sp1
|
CN1296711C
(zh)
*
|
2004-05-14 |
2007-01-24 |
沈阳迈迪生物医学技术有限公司 |
乳腺癌的Her-2免疫组织化学诊断试剂盒
|
WO2006010143A2
(en)
|
2004-07-13 |
2006-01-26 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
|
WO2006031811A2
(en)
|
2004-09-10 |
2006-03-23 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
EP3061461A1
(de)
|
2004-10-29 |
2016-08-31 |
ratiopharm GmbH |
Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
|
EP1838332A1
(de)
*
|
2005-01-06 |
2007-10-03 |
Neose Technologies, Inc. |
Glycokonjugation über saccharylfragmente
|
ES2449195T3
(es)
|
2005-01-10 |
2014-03-18 |
Ratiopharm Gmbh |
Factor estimulante de colonias de granulocitos glicopegilado
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
CN101171034B
(zh)
|
2005-03-03 |
2014-06-18 |
免疫医疗公司 |
人源化l243抗体
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
WO2006105426A2
(en)
*
|
2005-03-30 |
2006-10-05 |
Neose Technologies, Inc. |
Manufacturing process for the production of peptides grown in insect cell lines
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
US8067006B2
(en)
|
2005-04-06 |
2011-11-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
WO2006121569A2
(en)
*
|
2005-04-08 |
2006-11-16 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
US20110003744A1
(en)
*
|
2005-05-25 |
2011-01-06 |
Novo Nordisk A/S |
Glycopegylated Erythropoietin Formulations
|
JP5457671B2
(ja)
*
|
2005-07-28 |
2014-04-02 |
ノバルティス アーゲー |
M−csf特異的モノクローナル抗体およびその使用
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US8097237B2
(en)
*
|
2005-08-23 |
2012-01-17 |
Stc.Unm |
Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
|
JP4808453B2
(ja)
*
|
2005-08-26 |
2011-11-02 |
株式会社荏原製作所 |
研磨方法及び研磨装置
|
US20090130776A1
(en)
*
|
2005-09-01 |
2009-05-21 |
Canon Kabushiki Kaisha |
Binding protein molecule
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
KR20080077132A
(ko)
*
|
2005-12-12 |
2008-08-21 |
에프. 호프만-라 로슈 아게 |
가변 부위에 글리코실화된, 아밀로이드 베타 4에 대한 항체
|
EP2674440B1
(de)
|
2005-12-16 |
2019-07-03 |
IBC Pharmaceuticals, Inc. |
Polyvalente bioaktive anordnungen auf immunglobulinbasis
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
EP2046951B1
(de)
|
2006-07-05 |
2011-10-26 |
Catalyst Biosciences, Inc. |
Protease-screening-verfahren und dadurch identifizierte proteasen
|
US20080274958A1
(en)
*
|
2006-07-21 |
2008-11-06 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
CN101626783A
(zh)
*
|
2006-08-04 |
2010-01-13 |
诺华有限公司 |
Ephb3-特异性抗体和其应用
|
EP3415532A1
(de)
|
2006-08-18 |
2018-12-19 |
XOMA Technology Ltd. |
Prlr-spezifischer antikörper und verwendungen davon
|
US20080095414A1
(en)
*
|
2006-09-12 |
2008-04-24 |
Vladimir Desh |
Correction of functional nuclear imaging data for motion artifacts using anatomical data
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
US10925977B2
(en)
*
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
WO2008070780A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonist antibodies against ephb3
|
CN104043123B
(zh)
|
2007-01-25 |
2019-08-13 |
达娜-法勃肿瘤研究所公司 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
AU2008227123B2
(en)
|
2007-03-15 |
2014-03-27 |
Ludwig Institute For Cancer Research Ltd. |
Treatment method using EGFR antibodies and src inhibitors and related formulations
|
NZ580030A
(en)
|
2007-04-03 |
2012-06-29 |
Biogenerix Ag |
Methods of treatment using glycopegylated g-csf
|
CN102558001B
(zh)
|
2007-05-22 |
2015-09-23 |
惠氏有限责任公司 |
制造酰肼的改良方法
|
AU2014208212B2
(en)
*
|
2007-05-22 |
2016-07-28 |
Wyeth |
Improved processes for making hydrazides
|
WO2008154639A2
(en)
|
2007-06-12 |
2008-12-18 |
Neose Technologies, Inc. |
Improved process for the production of nucleotide sugars
|
MX2010001757A
(es)
|
2007-08-14 |
2010-09-14 |
Ludwig Inst Cancer Res |
Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
KR101224711B1
(ko)
*
|
2008-01-30 |
2013-01-21 |
유니버시티 오브 캔사스 |
림프관내 화학요법 약물 담체
|
KR101582841B1
(ko)
|
2008-02-27 |
2016-01-11 |
노보 노르디스크 에이/에스 |
콘쥬게이트된 인자 viii 분자
|
KR20110033233A
(ko)
*
|
2008-07-21 |
2011-03-30 |
이뮤노메딕스, 인코오포레이티드 |
개선된 치료 특성을 갖는 항체의 구조 변이체
|
LT3912643T
(lt)
|
2009-02-13 |
2023-02-10 |
Immunomedics Inc. |
Imunokonjugatai su ląstelės viduje skaldoma jungtimi
|
US8614185B2
(en)
*
|
2009-05-04 |
2013-12-24 |
Centocor Ortho Biotech Inc. |
Fusion proteins of alpha-MSH derivatives and Fc
|
EP3009455A1
(de)
|
2009-09-16 |
2016-04-20 |
Immunomedics Inc. |
Klasse-i-anti-cea-antikörper und verwendungen davon
|
TW201120210A
(en)
|
2009-11-05 |
2011-06-16 |
Hoffmann La Roche |
Glycosylated repeat-motif-molecule conjugates
|
CA2782194C
(en)
|
2009-12-02 |
2018-01-16 |
Immunomedics, Inc. |
Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
|
EP2523680A4
(de)
*
|
2010-01-11 |
2013-06-19 |
Ct Molecular Med & Immunology |
Verstärkte zytotoxizität von antikörpern gegen cd74 und hla-dr mit interferon-gamma
|
US9359439B2
(en)
*
|
2010-08-10 |
2016-06-07 |
Glycotope Gmbh |
Fab-glycosylated antibodies
|
US8956859B1
(en)
|
2010-08-13 |
2015-02-17 |
Aviex Technologies Llc |
Compositions and methods for determining successful immunization by one or more vaccines
|
CN103501825B
(zh)
|
2011-05-02 |
2017-03-15 |
免疫医疗公司 |
用于小体积施用的同种异型选择的抗体的超滤浓缩
|
US10865383B2
(en)
|
2011-07-12 |
2020-12-15 |
Lineage Cell Therapeutics, Inc. |
Methods and formulations for orthopedic cell therapy
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
EP2788020A4
(de)
|
2011-12-05 |
2015-04-29 |
Immunomedics Inc |
Therapeutische verwendung von anti-cd22-antikörpern zur induktion von trogozytose
|
US9745631B2
(en)
|
2011-12-20 |
2017-08-29 |
Dana-Farber Cancer Institute, Inc. |
Methods for diagnosing and treating oncogenic kras-associated cancer
|
CA2874521A1
(en)
|
2012-05-24 |
2013-11-28 |
Dana-Farber Cancer Institute, Inc. |
Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
|
WO2014014518A1
(en)
|
2012-07-18 |
2014-01-23 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating, preventing and predicting risk of developing breast cancer
|
WO2014028560A2
(en)
|
2012-08-14 |
2014-02-20 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
CN107753954A
(zh)
|
2012-12-13 |
2018-03-06 |
免疫医疗公司 |
功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
WO2015012904A2
(en)
|
2012-12-13 |
2015-01-29 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
PL2991683T3
(pl)
|
2013-05-02 |
2020-03-31 |
Glykos Finland Oy |
Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
WO2015053871A2
(en)
|
2013-08-26 |
2015-04-16 |
MabVax Therapeutics, Inc. |
NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
|
WO2015050844A1
(en)
|
2013-10-01 |
2015-04-09 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancer with atovaquone-related compounds
|
WO2015126548A1
(en)
|
2014-02-21 |
2015-08-27 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to trop-2 expressing cells
|
CN106029098A
(zh)
|
2014-02-25 |
2016-10-12 |
免疫医疗公司 |
人源化rfb4抗cd22抗体
|
US10350264B2
(en)
|
2014-03-27 |
2019-07-16 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
|
ES2863074T3
(es)
|
2014-06-04 |
2021-10-08 |
Biontech Res And Development Inc |
Anticuerpos monoclonales humanos contra el gangliósido GD2
|
EP3160504B1
(de)
|
2014-06-24 |
2020-09-16 |
Immunomedics, Inc. |
Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
|
WO2015197919A1
(en)
|
2014-06-25 |
2015-12-30 |
Glykos Finland Oy |
Antibody drug conjugates binding to high-mannose n-glycan
|
US10973920B2
(en)
|
2014-06-30 |
2021-04-13 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
CN117138060A
(zh)
|
2014-10-07 |
2023-12-01 |
免疫医疗公司 |
抗体-药物缀合物的新辅助剂用途
|
CN107428837A
(zh)
|
2015-04-22 |
2017-12-01 |
免疫医疗公司 |
循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
|
CN113999312A
(zh)
|
2015-06-24 |
2022-02-01 |
豪夫迈·罗氏有限公司 |
具有定制亲和力的抗转铁蛋白受体抗体
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
SI3313443T1
(sl)
|
2015-06-25 |
2023-11-30 |
Immunomedics, Inc. |
Kombiniranje protiteles proti HLA-DR ali proti TROP-2 z zaviralci mikrotubulov, zaviralci PARP, zaviralci brutonove kinaze ali zaviralci fosfoinozitid 3-kinaze pomembno izboljša izid zdravljenja pri raku
|
SI3316885T1
(sl)
|
2015-07-01 |
2021-09-30 |
Immunomedics, Inc. |
Imunokonjugati protitelo-SN-38 z linkerjem CL2A
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
AU2016333512B2
(en)
|
2015-10-02 |
2022-11-17 |
F. Hoffmann-La Roche Ag |
Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
|
CN108601841A
(zh)
|
2016-02-10 |
2018-09-28 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
|
WO2017189279A1
(en)
|
2016-04-27 |
2017-11-02 |
Immunomedics, Inc. |
Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
|
AU2017277288A1
(en)
|
2016-06-09 |
2019-01-24 |
Omeros Corporation |
Monoclonal antibodies, compositions and methods for detecting mucin -like protein (MLP) as a biomarker for ovarian and pancreatic cancer
|
CN110392570A
(zh)
|
2017-03-27 |
2019-10-29 |
免疫医疗公司 |
用沙妥珠单抗格维替康和rad51抑制剂治疗表达trop-2的三阴性乳腺癌
|
EP3606964A4
(de)
|
2017-04-03 |
2020-12-09 |
Immunomedics, Inc. |
Subkutane verabreichung von antikörper-arzneimittelkonjugaten zur krebstherapie
|
US11891451B2
(en)
*
|
2017-05-11 |
2024-02-06 |
Vib Vzw |
Glycosylation of variable immunoglobulin domains
|
JP7256796B2
(ja)
|
2017-10-13 |
2023-04-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Thomsen-nouvelle(tn)抗原に対するヒト抗体
|
BR112020023373A2
(pt)
|
2018-05-18 |
2021-02-09 |
Daiichi Sankyo Company, Limited |
conjugado, composição, e, uso de um conjugado ou de uma composição
|
CN109270064B
(zh)
*
|
2018-11-12 |
2020-12-01 |
新乡医学院 |
一种基于葡聚糖微球的免疫沉淀试剂及其制备方法与应用
|
CA3131705A1
(en)
|
2019-03-27 |
2020-10-01 |
Umc Utrecht Holding B.V. |
Engineered iga antibodies and methods of use
|
WO2022226420A2
(en)
*
|
2021-04-23 |
2022-10-27 |
University Of Maryland, College Park |
An fc glycan remodeling platform method for site-specific antibody conjugation and applications thereof
|
EP4342497A1
(de)
|
2021-05-10 |
2024-03-27 |
Kawasaki Institute of Industrial Promotion |
Antikörper mit reduzierter bindungsaffinität für antigen
|